Company insiders — CEOs, CFOs, directors and 10% owners — buying their own company's stock on the open market: every purchase of $250K or more from the previous day's Form 4 filings, largest first, with an AI summary of the day.
| Stock | Insider | Value | Type | |||
|---|---|---|---|---|---|---|
| SCTXScribe Therapeutics Inc. | Carl L. GordonDirector | $15.0M | New stake | |||
| IPO purchase at $15.00/share; SCTX now $18.36 (+22.4% since buy). Gordon is a Partner at OrbiMed Advisors; companion Form 4 also filed by OrbiMed Advisors LLC (accession 0000947871-26-000733) for the same transaction. Part of a $56M+ cluster buy at the SCTX IPO alongside Avoro/Aghazadeh ($36M, filed July 28) and Andreessen Horowitz ($5M). | ||||||
| SCTXScribe Therapeutics Inc. | Marc L. Andreessen10% Owner / Venture Investor (Andreessen Horowitz) | $5.00M | New stake | |||
| IPO purchase at $15.00/share via AH Bio Fund II, L.P.; filing also names Ben Horowitz. SCTX now $18.36 (+22.4% since buy). a16z also received 2,749,392 shares from preferred-stock conversions (AH Bio Funds II & III). Stock ran to $22.31 on first trading day before pulling back to $18.36. | ||||||
Scanned the last 24 hours of EDGAR Form 4 filings (151+ Form 4s reviewed, filed July 29–30, 2026). 2 qualifying buys (≥ $250K, transaction type P) totalling $20.0M — both concentrated in Scribe Therapeutics (SCTX), which completed its IPO on July 27, 2026 at $15/share. A third leg of the cluster, Avoro Capital / Behzad Aghazadeh, filed one day earlier (July 28) for $36.1M in combined SCTX purchases and is included in notes for completeness.
Scribe Therapeutics IPO cluster buy — the dominant story of July 29–30. SCTX is a CRISPR base-editing company that priced its IPO at $15/share on July 23–24 and began trading July 27. The stock immediately ran to $22.31 on first-day enthusiasm before pulling back to $18.36 (still +22% vs. IPO price; volume is very thin at 103 shares today — freshly listed).
Three major biotech-focused institutional investors filed Form 4s within 48 hours of the IPO:
Combined across all three: ≈$56M committed to SCTX at or near IPO pricing, signaling exceptional conviction from elite biotech and tech investors. Jennifer Doudna (Nobel laureate, CRISPR co-inventor) holds ~603K shares via preferred-stock conversion and is listed as a 10% Owner, adding scientific credibility.
Broader universe check: All other notable July 29 insiders in the 151+ filings reviewed were 10b5-1 plan sellers, RSU tax-withholding filers, or option exercisers. No other open-market P-coded purchases ≥ $250K were found outside the SCTX cluster on July 29–30.
Sectors: Biotech / Gene Editing (IPO cluster). No industrial, financial, or energy insider buys qualified today.
Source: insiders' SEC Form 4 filings — open-market purchases (transaction code P) of $250K or more filed in the previous day. Insiders must file within two business days of a trade, so a purchase can be a day or two older than its filing. Average price = value ÷ shares. Insiders buy for many reasons and a purchase is no guarantee the shares will rise. The summaries are written by AI as a research aid — not financial advice or a recommendation to buy or sell any security, and they can be wrong.
SPX Lens Insider Buying reads the SEC Form 4 filings insiders file after trading their own company's stock and lists every open-market purchase of $250K or more — who bought, their role, how much and at what average price. Insiders sell for many reasons, but they usually buy for one: they think the shares are worth more. It is free, and a new scan is posted every trading day. How to read insider buying →
See where SPX is heading next. The SPX Lens chart shows key levels, live signals and an AI forecast for the next bars — free to try.
Open the live chartOpen in the Stocks tab© SPX Lens · About · Terms · Privacy — for educational purposes only, not financial advice.